Quantbot Technologies LP Purchases New Position in LifeMD, Inc. (NASDAQ:LFMD)

Quantbot Technologies LP acquired a new stake in LifeMD, Inc. (NASDAQ:LFMD) in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 11,982 shares of the company’s stock, valued at approximately $59,000.

Several other hedge funds also recently made changes to their positions in LFMD. Rhumbline Advisers lifted its holdings in shares of LifeMD by 6.1% in the 4th quarter. Rhumbline Advisers now owns 48,689 shares of the company’s stock valued at $241,000 after purchasing an additional 2,814 shares during the last quarter. Magnus Financial Group LLC increased its position in LifeMD by 31.1% during the fourth quarter. Magnus Financial Group LLC now owns 16,000 shares of the company’s stock worth $79,000 after buying an additional 3,792 shares during the period. Los Angeles Capital Management LLC lifted its stake in LifeMD by 4.8% in the fourth quarter. Los Angeles Capital Management LLC now owns 127,435 shares of the company’s stock valued at $631,000 after buying an additional 5,850 shares during the last quarter. Charles Schwab Investment Management Inc. boosted its holdings in shares of LifeMD by 5.9% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 108,478 shares of the company’s stock valued at $537,000 after acquiring an additional 6,034 shares during the period. Finally, Intech Investment Management LLC purchased a new position in shares of LifeMD during the third quarter worth approximately $54,000. Hedge funds and other institutional investors own 35.52% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms recently commented on LFMD. B. Riley upgraded shares of LifeMD to a “strong-buy” rating in a research report on Tuesday, March 11th. HC Wainwright lifted their price objective on shares of LifeMD from $12.00 to $14.00 and gave the company a “buy” rating in a research note on Wednesday, March 12th. KeyCorp decreased their target price on shares of LifeMD from $10.00 to $7.00 and set an “overweight” rating for the company in a research note on Wednesday, January 8th. Lake Street Capital began coverage on LifeMD in a report on Tuesday, December 10th. They set a “buy” rating and a $12.00 price target on the stock. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and set a $15.00 price objective on shares of LifeMD in a research note on Tuesday, March 11th. One research analyst has rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, LifeMD has a consensus rating of “Buy” and a consensus target price of $11.43.

LifeMD Stock Down 0.2 %

Shares of NASDAQ:LFMD opened at $5.43 on Wednesday. LifeMD, Inc. has a fifty-two week low of $3.99 and a fifty-two week high of $12.88. The firm’s 50-day simple moving average is $5.84 and its 200-day simple moving average is $5.44. The company has a market cap of $242.09 million, a price-to-earnings ratio of -8.48 and a beta of 1.50.

LifeMD (NASDAQ:LFMD) last announced its quarterly earnings data on Monday, March 10th. The company reported ($0.02) EPS for the quarter, beating analysts’ consensus estimates of ($0.04) by $0.02. The firm had revenue of $64.26 million during the quarter, compared to analyst estimates of $57.43 million. On average, research analysts forecast that LifeMD, Inc. will post -0.56 EPS for the current year.

Insider Activity

In other LifeMD news, CMO Jessica Friedeman sold 30,000 shares of the company’s stock in a transaction dated Friday, March 14th. The shares were sold at an average price of $5.66, for a total transaction of $169,800.00. Following the transaction, the chief marketing officer now directly owns 170,000 shares in the company, valued at approximately $962,200. This represents a 15.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, CEO Justin Schreiber sold 50,000 shares of the stock in a transaction dated Friday, February 14th. The shares were sold at an average price of $7.55, for a total transaction of $377,500.00. Following the completion of the transaction, the chief executive officer now directly owns 2,653,715 shares of the company’s stock, valued at approximately $20,035,548.25. This trade represents a 1.85 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 105,000 shares of company stock valued at $677,050 in the last three months. 15.97% of the stock is currently owned by company insiders.

LifeMD Profile

LifeMD, Inc operates as a direct-to-patient telehealth company that connects consumers to healthcare professionals for medical care in the United States. The company offers telehealth platform comprising RexMD, a men's telehealth brand that provides access to virtual medical treatment for a variety of men's health needs from licensed physician; ShapiroMD that provides virtual medical treatment, prescription medications, patented doctor formulated OTC products, topical compounded medications, and medical devices treating male and female hair loss; NavaMD, a female-oriented tele-dermatology that offers virtual medical treatment from dermatologists and other providers; and prescription oral and compounded topical medications to treat aging and acne; and Cleared which provides personalized treatments for allergy, asthma and immunology, including in-home tests for both environmental and food allergies, prescriptions for allergies and asthma and immunotherapies for treating chronic allergies.